Mental DailyMental Daily
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • More
    • Opinion
    • My Bookmarks
Aa
Mental Daily
Aa
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • Opinion
Search
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • More
    • Opinion
    • My Bookmarks
Follow US
  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store
© 2022 - Mental Daily. All Rights Reserved.
Health

Merck seeks FDA authorization for antiviral drug treatment molnupiravir

Staff Writer
Staff Writer 1 year ago
Updated 2021/10/23 at 1:39 PM
Share
SHARE

Pharmaceutical giant Merck and Ridgeback are seeking authorization from the U.S. Food and Drug Administration (FDA) for the release and distribution of its new hallmark anti-COVID drug treatment.

If given the green light by the FDA, it would be the first COVID-19 treatment via oral administration with the potential to reduce symptoms of the coronavirus, as well as lower the mortality risk, in mild-to-moderate cases among adults.

“At the interim analysis, molnupiravir reduced the risk of hospitalization or death by approximately 50%; 7.3% of patients who received molnupiravir were either hospitalized or died through Day 29 following randomization, compared with 14.1% of placebo-treated patients,” a Merck press release reads.

“We are grateful to the clinical investigators and patients who have helped bring us to this important milestone. Without their significant contributions, today’s achievement would not be possible. The submission to the FDA is a critical step towards making molnupiravir available to people who may benefit from an oral antiviral medicine that can be taken at home shortly after diagnosis with COVID-19,” the press release also states.


“We are pleased to partner with Merck and regulatory authorities to help provide molnupiravir to the people who need it here in the U.S. and around the world.”

Molnupiravir is said to work by inhibiting the replication of SARS-Cov-2, thus reducing the severity of symptoms.

The FDA is set to review its authorization request within the next few weeks.

Photo: ASSOCIATED PRESS

You Might Also Like

Machine learning research suggests drugs that may decrease cigarette smoking

New research explores the association between viral infection and Alzheimer’s disease

Study suggests mindfulness may help adolescents overcome traumas

Researchers find pregnancy length is shorter among Americans than Europeans

Study suggests gut microbes may control body temperature

TAGGED: COVID-19, epidemiology, Merck, molnupiravir
Staff Writer October 11, 2021
Share this Article
Facebook Twitter Whatsapp Whatsapp Email Print
Previous Article Natural outdoor light could impact mood and increase sleep quality
Next Article Researchers test new type of TMPRSS2 inhibitors for inhibiting COVID-19 infection

Recommended

Health

Machine learning research suggests drugs that may decrease cigarette smoking

1 Min Read
Health

New research explores the association between viral infection and Alzheimer’s disease

1 Min Read
Health

Study suggests mindfulness may help adolescents overcome traumas

1 Min Read
Health

Researchers find pregnancy length is shorter among Americans than Europeans

1 Min Read
//

We are a trusted online source for research news and resources on all aspects of the mind and human behavior.

Verticals

  • Clinical
  • Health
  • Social
  • I/O
  • Opinion

Social

  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store

Links

  • About
  • Contact
  • The Editor
  • Terms & Conditions
  • Privacy Policy
Follow US

© 2022 Mental Daily. All Rights Reserved.

  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store

Removed from reading list

Undo
Welcome Back!

Sign in to your account

Lost your password?